Current treatment for erectile dysfunction: an umbrella review of systematic reviews and meta-analyses.

IF 3 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Aging Male Pub Date : 2026-12-31 Epub Date: 2026-03-06 DOI:10.1080/13685538.2026.2640765
Jian Ma, Jintao Wei, Jinze Li, Maobin Yu, Shikuan Lu, Hongsen Zeng, Lei Xu, Ye Dong, Ziyang Ma, Peihai Zhang
{"title":"Current treatment for erectile dysfunction: an umbrella review of systematic reviews and meta-analyses.","authors":"Jian Ma, Jintao Wei, Jinze Li, Maobin Yu, Shikuan Lu, Hongsen Zeng, Lei Xu, Ye Dong, Ziyang Ma, Peihai Zhang","doi":"10.1080/13685538.2026.2640765","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This umbrella review aimed to summarize and provide a general evaluation of the effectiveness of current treatments for erectile dysfunction (ED) and assess the quality of evidence.</p><p><strong>Methods: </strong>This umbrella review available in PubMed, Web of Science, the Cochrane Library, and Embase, covering studies published up to October 2025, was conducted. The International Index of Erectile Function (IIEF) or its simplified version and the erectile hardness score (EHS) were used as endpoints to evaluate the effectiveness of the treatments.</p><p><strong>Results: </strong>Of 1191 studies, 23 published meta-analyses were extracted, yielding 42 summary effects on IIEF (<i>n </i>= 20), the international index of erectile function-5 (IIEF-5) (<i>n </i>= 9), the international index of erectile function-erectile function (IIEF-EF) (<i>n </i>= 6), and EHS (<i>n </i>= 7) on 36 interventions. All meta-analyses were analyzed via the AMSTAR-2, of which 13 (56.5%) were rated as critically low quality, 7 (30.5%) were rated as low quality, 2 (8.7%) were rated as moderate quality, and 1 (4.3%) was rated as high quality. Of the 42 summary effects, only two studies were rated as high-quality and moderate-quality respectively, whereas 47.6% (<i>n </i>= 20) and 47.6% (<i>n </i>= 20) were rated low and very low, respectively.</p><p><strong>Conclusions: </strong>The current evidence base for ED treatments is predominantly of low or very low quality. While statistically significant improvements in ED were observed with both pharmacological and nonpharmacological interventions, these findings should be interpreted with caution due to the limited number of patients and the subjective nature of outcome indicators. The treatment landscape for ED is increasingly diverse, yet the reliability of the evidence is poor. Further well-designed studies on single treatments and high-quality meta-analyses of intertreatment comparisons are urgently recommended.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":"29 1","pages":"2640765"},"PeriodicalIF":3.0000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2026.2640765","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This umbrella review aimed to summarize and provide a general evaluation of the effectiveness of current treatments for erectile dysfunction (ED) and assess the quality of evidence.

Methods: This umbrella review available in PubMed, Web of Science, the Cochrane Library, and Embase, covering studies published up to October 2025, was conducted. The International Index of Erectile Function (IIEF) or its simplified version and the erectile hardness score (EHS) were used as endpoints to evaluate the effectiveness of the treatments.

Results: Of 1191 studies, 23 published meta-analyses were extracted, yielding 42 summary effects on IIEF (n = 20), the international index of erectile function-5 (IIEF-5) (n = 9), the international index of erectile function-erectile function (IIEF-EF) (n = 6), and EHS (n = 7) on 36 interventions. All meta-analyses were analyzed via the AMSTAR-2, of which 13 (56.5%) were rated as critically low quality, 7 (30.5%) were rated as low quality, 2 (8.7%) were rated as moderate quality, and 1 (4.3%) was rated as high quality. Of the 42 summary effects, only two studies were rated as high-quality and moderate-quality respectively, whereas 47.6% (n = 20) and 47.6% (n = 20) were rated low and very low, respectively.

Conclusions: The current evidence base for ED treatments is predominantly of low or very low quality. While statistically significant improvements in ED were observed with both pharmacological and nonpharmacological interventions, these findings should be interpreted with caution due to the limited number of patients and the subjective nature of outcome indicators. The treatment landscape for ED is increasingly diverse, yet the reliability of the evidence is poor. Further well-designed studies on single treatments and high-quality meta-analyses of intertreatment comparisons are urgently recommended.

当前勃起功能障碍的治疗:系统综述和荟萃分析的综述。
目的:本综述旨在总结和提供目前治疗勃起功能障碍(ED)的有效性的一般评价,并评估证据的质量。方法:本综述可在PubMed、Web of Science、Cochrane Library和Embase中找到,涵盖截至2025年10月发表的研究。以国际勃起功能指数(IIEF)或其简化版和勃起硬度评分(EHS)作为评价治疗效果的终点。结果:在1191项研究中,提取了23项已发表的荟萃分析,对IIEF (n = 20)、国际勃起功能指数-5 (IIEF-5) (n = 9)、国际勃起功能指数-勃起功能(IIEF- ef) (n = 6)和EHS (n = 7)的36项干预措施产生了42项综合效应。所有meta分析均通过AMSTAR-2进行分析,其中13例(56.5%)被评为极低质量,7例(30.5%)被评为低质量,2例(8.7%)被评为中等质量,1例(4.3%)被评为高质量。在42个总结效应中,只有两个研究分别被评为高质量和中等质量,而47.6% (n = 20)和47.6% (n = 20)的研究分别被评为低质量和极低质量。结论:目前ED治疗的证据基础主要是低质量或极低质量。虽然通过药物和非药物干预均观察到ED的统计学显著改善,但由于患者数量有限和结果指标的主观性质,这些发现应谨慎解释。ED的治疗方案越来越多样化,但证据的可靠性却很差。迫切需要进一步设计良好的单一治疗研究和高质量的治疗间比较荟萃分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Aging Male
Aging Male 医学-泌尿学与肾脏学
CiteScore
6.40
自引率
3.80%
发文量
33
审稿时长
>12 weeks
期刊介绍: The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书